{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:54:06Z","timestamp":1791820446777,"version":"4.3.4"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>This study aimed to develop a placebo response model for pharmaceutical clinical trials of primary Sjogren\u2019s syndrome,and to quantitatively analyze the distribution and related factors influencing the placebo response to further optimize the design of clinical trials and evaluate the results of single-arm clinical trials. Public databases, including PubMed, Embase, and Cochrane Library were searched for reports on randomized placebo-controlled trials for Sj\u00f6gren\u2019s syndrome which used the change from baseline in ESSDAI score as the primary outcome. The model-based meta-analysis method was used to evaluate the time course and the related influencing factors of the placebo response for ESSDAI in such clinical trials. A virtual placebo control group was constructed based on the final placebo response model to determine the treatment efficacy of belimumab and cyclosporine A for primary Sj\u00f6gren\u2019s syndrome in a single-arm study. A total of 12 studies involving 450 subjects were included in the analysis. The established model described the time-course characteristics of the changes in ESSDAI score from the baseline in the 48 weeks placebo group. We found that the onset time of placebo response was approximately 12 weeks, and its efficacy plateaued at 48 weeks. The baseline ESSDAI score had a significant effect on the maximum value of the placebo response; the maximum value of the placebo response decreased by 0.552 for every 1 score rise in the baseline ESSDAI score. The efficacy of belimumab and cyclosporine A in the single-arm trial was comparable to that of the placebo response at the same baseline; no significant therapeutic advantage was observed. The placebo response model established in this study could provide a basis for designing clinical trials for primary Sjogren\u2019s syndrome in the future. It may also provide a reliable external efficacy control standard for single-arm clinical trials.<\/jats:p>","DOI":"10.3389\/fimmu.2021.783246","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T06:04:05Z","timestamp":1637042645000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Development and Application of the Placebo Response Model in Clinical Trials for Primary Sj\u00f6gren\u2019s Syndrome"],"prefix":"10.3389","volume":"12","author":[{"given":"ZHI-Zhou","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Shan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"B1","first-page":"1","article-title":"Epidemiology of Sj\u00f6gren\u2019s Syndrome: Where Are We Now","volume":"25","author":"Binard","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.11.004","article-title":"The Geoepidemiology of Sj\u00f6gren\u2019s Syndrome","volume":"9","author":"Mavragani","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205375","article-title":"Epidemiology of Primary Sj\u00f6gren\u2019s Syndrome: A Systematic Review and Meta-Analysis","volume":"74","author":"Qin","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh170","article-title":"Measurement of Fatigue and Discomfort in Primary Sjogren's Syndrome Using a New Questionnaire Tool","volume":"43","author":"Bowman","year":"2004","journal-title":"Rheumatol (Oxford)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(73)90021-8","article-title":"Sj\u00f6gren's Syndrome\u2014A Clinical Review","volume":"2","author":"Mason","year":"1973","journal-title":"Semin Arthritis rheumatism"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.08.001","article-title":"Diagnostic Value of Labial Minor Salivary Gland Biopsy for Sjogren's Syndrome: A Systematic Review","volume":"12","author":"Guellec","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/art.21990","article-title":"Quality of Life and Psychological Status in Patients With Primary Sjogren's Syndrome and Sicca Symptoms Without Autoimmune Features","volume":"15","author":"Champey","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66990-5","article-title":"Sjogren\u2019s Syndrome","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet (London England)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2012.53","article-title":"Topical and Systemic Medications for the Treatment of Primary Sj\u00f6gren\u2019s Syndrome","volume":"8","author":"Ramos-Casals","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1014","article-title":"Treatment of Primary Sjogren Syndrome: A Systematic Review","volume":"304","author":"Ramos-Casals","year":"2010","journal-title":"Jama"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbr.2015.07.004","article-title":"Recommendations for the Treatment of Sjogren\u2019s Syndrome","volume":"55","author":"Valim","year":"2015","journal-title":"Rev Bras Reumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR Recommendations for the Management of Sj\u00f6gren\u2019s Syndrome With Topical and Systemic Therapies","volume":"12","author":"Ramos-Casals","year":"2019","journal-title":"Ann Rheumatic Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"102364","DOI":"10.1016\/j.jaut.2019.102364","article-title":"Sj\u00f6gren's Syndrome: Old and New Therapeutic Targets","volume":"110","author":"Clio","year":"2020","journal-title":"J Autoimmun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23917","article-title":"Meta-Analysis of Treatment for Primary Sj\u00f6gren's Syndrome","volume":"72","author":"Chu","year":"2020","journal-title":"Arthritis Care Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0133907","DOI":"10.1371\/journal.pone.0133907","article-title":"Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sj\u00f6gren's Syndrome","volume":"10","author":"Devauchelle-Pensec","year":"2017","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/1759720X17746319","article-title":"Management of Primary Sj\u00f6gren\u2019s Syndrome: Recent Developments and New Classification Criteria","volume":"10","author":"Del Papa","year":"2018","journal-title":"Ther Adv Musculoskeletal Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sj\u00f6gren\u2019s Syndrome Disease Activity Index (ESSDAI): Development of a Consensus Systemic Disease Activity Index in Primary Sj\u00f6gren\u2019s Syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/psp4.12041","article-title":"The Many Flavors of Model-Based Meta-Analysis: Part I Introduction and Landmark Data","volume":"5","author":"Boucher","year":"2016","journal-title":"CPT-Pharmacomet Syst"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12299","article-title":"Many Flavors of Model-Based Meta-Analysis: Part II - Modeling Summary Level Longitudinal Responses","volume":"7","author":"Boucher","year":"2018","journal-title":"CPT-Pharmacomet Syst"},{"key":"B20","first-page":"S38","article-title":"Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration","volume":"5","author":"Higgins","year":"2011","journal-title":"N-S Arch Ex Path Ph"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061469","article-title":"Building Population Pharmacokinetic Pharmacodynamic Models. I. Models for Covariate Effects","volume":"20","author":"Mandema","year":"1992","journal-title":"J Pharmacokinet Biop"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","article-title":"Stability and Performance of a Population Pharmacokinetic Model","volume":"37","author":"Ette","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106440","article-title":"Jackknife Empirical Likelihood Confidence Intervals for Assessing Heterogeneity in Meta-Analysis of Rare Binary Event Data","volume":"107","author":"Wang","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"B24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0091270010390040","article-title":"Standardized Visual Predictive Check Versus Visual Predictive Check for Model Evaluation","volume":"52","author":"Wang","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-016-9487-8","article-title":"Improving the Estimation of Parameter Uncertainty Distributions in Nonlinear Mixed Effects Models Using Sampling Importance Resampling","volume":"43","author":"Anne-Ga\u00eblle","year":"2016","journal-title":"J Pharmacokinet Pharmacodynamics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and Safety of Belimumab in Primary Sj\u00f6gren's Syndrome: Results of the BELISS Open-Label Phase II Study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheumatic Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3360-4","article-title":"A Phase II Investigator-Initiated Pilot Study With Low-Dose Cyclosporine A for the Treatment of Articular Involvement in Primary Sj\u00f6gren\u2019s Syndrome","volume":"35","author":"Claudia","year":"2016","journal-title":"Clin Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sj\u00f6gren Syndrome: The JOQUER Randomized Clinical Trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1085","article-title":"Treatment of Primary Sj\u00f6gren Syndrome With Rituximab: A Randomized Trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/art.40093","article-title":"Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sj\u00f6gren's Syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/art.40513","article-title":"Clinical Efficacy and Safety of Baminercept, a Lymphotoxin \u03b2 Receptor Fusion Protein, in Primary Sj\u00f6gren's Syndrome: Results From a Phase II Randomized, Doubleblind, Placebo-Controlled Trial","volume":"70","author":"St Clair","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of Primary Sj\u00f6gren\u2019s Syndrome With Ianalumab (VAY736) Targeting B Cells by BAFF Receptor Blockade Coupled With Enhanced, Antibody-Dependent Cellular Cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann Rheumatic Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa410","article-title":"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Oral Seletalisib in Primary Sj\u00f6gren's Syndrome","volume":"60","author":"Juarez","year":"2020","journal-title":"Rheumatol (Oxford England)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/art.41489","article-title":"Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sj\u00f6gren\u2019s Syndrome: A Randomized Clinical Trial","volume":"73","author":"Posada","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept Treatment for Patients With Early Active Primary Sj\u00f6gren\u2019s Syndrome: A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial (ASAP-III Study)","volume":"2","author":"Van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide\u2013hydroxychloroquine Combination Therapy in Patients With Primary Sj\u00f6gren's Syndrome (RepurpSS-I): A Placebo-Controlled, Double-Blinded, Randomised Clinical Trial","volume":"2","author":"van der Heijden","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the Anti-CD40 Antibody Iscalimab in Patients With Primary Sj\u00f6gren's Syndrome: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept Study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and Safety of Abatacept in Active Primary Sj\u00f6gren's Syndrome: Results of a Phase III, Randomised, Placebo-Controlled Trial","volume":"80","author":"Baer Alan","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"annrheumdis-2020-218467","DOI":"10.1136\/annrheumdis-2021-219882","article-title":"Interleukin 6 Receptor Inhibition in Primary Sj\u00f6gren Syndrome: A Multicentre Double-Blind Randomised Placebo-Controlled Trial","author":"Felten","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jbspin.2017.06.004","article-title":"Efficacy and Safety of Biological DMARDs Modulating B Cells in Primary Sj\u00f6gren's Syndrome: Systematic Review and Meta-Analysis","volume":"85","author":"Letaief","year":"2018","journal-title":"Joint Bone Spine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2014-000022","article-title":"EULAR Sj\u00f6gren\u2019s Syndrome Disease Activity Index (ESSDAI): A User Guide","volume":"1","author":"Seror","year":"2015","journal-title":"RMD Open"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-4182(04)80071-1","article-title":"Correlation Between Corneal Sensitivity, Subjective Dry Eye Symptoms and Corneal Staining in Sjogren\u2019s Syndrome","volume":"39","author":"Adatia","year":"2004","journal-title":"Can J Ophthalmol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.783246\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T06:04:12Z","timestamp":1637042652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.783246\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2021.783246"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.783246","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"article-number":"783246"}}